Immumeds Inc. is a pioneering private therapeutic antibody company dedicated to revolutionizing the field of organ transplantation. Our proprietary antibody platform and pipeline portfolio target the global antibody market, valued at approximately $84.5 billion in 2017, with a compound annual growth rate (CAGR) of 6.3%.

Our lead product, Anti-Lymphocyte Globulin (ALG), has already demonstrated significant clinical success. With $66 million invested to date in research and development, ALG is poised for Phase III clinical trial.

ALG has been administered to over 52,000 organ transplant recipients across more than 281 transplant centers in the U.S., Canada, and parts of Europe. Its primary indication is induction therapy for the prevention of acute rejection, with a robust scientific record proving its efficacy and safety. Support from key opinion leaders (KOLs) in the transplant field further underscores the potential of ALG to transform transplantation practices.

Immumeds Inc. is committed to expanding recipient eligibility and enabling universal organ donor transplants. Our mission is to build a leading organ transplantation business by leveraging our innovative antibody platform. This transformative approach aims to address the critical challenges in transplantation, ultimately improving patient outcomes and increasing the availability of viable organs.

Our strategic focus includes advancing ALG through Phase III trial, expanding our product pipeline, and establishing partnerships with leading transplant centers and research institutions. Immumeds Inc. is well-positioned to capitalize on the growing demand for advanced therapeutic antibodies, driven by our commitment to innovation, clinical excellence, and patient-centric solutions.

As we continue to push the boundaries of medical science, Immumeds Inc. remains dedicated to transforming the field of organ transplantation, making life-saving treatments more accessible and effective for patients worldwide.